Fan W, Nittala MG, Wykoff CC, Brown DM, Uji A, Hemert JV, Fleming A, Robertson G, Sadda SR, Ip M. New biomarker quantifying the effect of anti-vegf therapy in eyes with proliferative diabetic retinopathy on ultra-wide field fluorescein angiography: recovery study. Retina - J Ret Vit Dis. 2022 Mar 1;42(3):426-33. doi: 10.1097/IAE.0000000000003358
Sauchelli S, Bradley J, Cox J, England C, Perry R. Weight maintenance interventions for people with type 2 diabetes mellitus: a systematic review protocol. Syst Rev. 2020 Sep 12;9(1):210. doi: 10.1186/s13643-020-01467-7
Demeyin (Nuabor) WA, Frost J, Ukoumunne OC, Briscoe S, Britten N. N of 1 trials and the optimal individualisation of drug treatments: a systematic review protocol. Syst Rev. 2017 Apr 24;6(1):90. doi: 10.1186/s13643-017-0479-6
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Feltner D, Hill C, Lenderking W, Williams VS, Morlock R. Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial. J Psychiatr Res. 2009 Oct;43(15):1224-30.
Morlock RJ, Williams VS, Cappelleri JC, Harness J, Fehnel SE, Endicott J, Feltner D. Development and evaluation of the Daily Assessment of Symptoms – Anxiety (DAS-A) Scale to evaluate onset of symptom relief in patients with generalized anxiety disorder. J Psychiatr Res. 2008 Oct;42(12):1024-36.